The project gathers 15 institutions of Chile, USA and Europe, like Cedenna, and seeks to develop, analyze and test new therapies for treating colorectal cancer by means of magnetic nanostructures. The initiative also has the purpose of promoting human capital exchange, technology transfer and the creation of new knowledge.
15 organizations, including the Center for the Development of Nanoscience and Nanotechnology (Cedenna) of Universidad de Santiago de Chile, joined to form the Magnamed consortium and respond to the call by the EU’s research grant program that will fund the project for at least four years. Other members of the consortium are the Complutense University of Madrid, the University of the Basque Country, the University of California, San Diego and IMG Pharma. The goal of this group is to work in collaboration and find new methods to treat colorectal cancer using state-of-the-art magnetic nanostructures to directly target and destroy tumor cells and avoid the side effects of treatments like radiotherapy and chemotherapy.
“Nanotechnology has a strong impact on different aspects of daily life. Its applications are expanding and being increasingly enhanced, reaching fields like medicine, where the search for new cancer treatments has gained interest and raised expectations, as conventional therapies are still expensive and complex and their side effects leave deep marks in the body,” Dr Dora Altbir, director of Cedenna, says.
The challenge is to create nanometric-sized disc-shaped structures that can be introduced in the body to destroy malignant cells thanks to their magnetic properties, without affecting healthy cells. This type of therapy has been studied for a while, but elaborating magnetic nanoparticles that effectively interact with biosensors and which are not derived from biotoxic materials has made the European Union to promote international cooperation among universities, research center and laboratories around the world to find new solutions and reduce cancer mortality.
“For Cedenna, the fact of participating in this project represents an opportunity to contribute with a potential solution to one of the most catastrophic and fatal diseases, to learn, and to work in collaboration with different institutions. This will give us the possibility of transferring that new knowledge and share with other scientists,” Dr Altbir says. The center was already awarded funds to collaborate.
Selective treatment
An effective treatment at an early stage of the disease is key to reducing mortality in some types of cancer like colon or rectal cancer. The challenge in clinical trials lies in that cancer cells are difficult to detect because of low concentrations of tumor biomarkers, which become perceptible at advanced stages. But the most common treatments are aggressive and non-selective.
Magnetic nanoparticles bind to malignant cells, contributing to early cancer detection. However, as their application is limited, Magnamed will explore the potential of emerging technologies based on magnetic nanostructures, which design can result in a better response.
Translated by Marcela Contreras